Open Access BASE2019

Future of the drug label:Perspectives from a multistakeholder dialogue

In: Gispen-de Wied , C C , Weemers , J , Boon , W , Mol , P G M & Stolk , P 2019 , ' Future of the drug label : Perspectives from a multistakeholder dialogue ' , British Journal of Clinical Pharmacology . https://doi.org/10.1111/bcp.14070 ; ISSN:0306-5251

Gispen-de Wied, Christine C; Weemers, Just; Boon, Wouter; Mol, Peter G. M; Stolk, Pieter

Open Access

Abstract

Regulating drugs does not end when market access has been granted. Monitoring drugs over the life cycle has become state of the art, inherent to evolving legislation and societal need. Here, we explore how the drug label could move along in a changing playing-field and become a sustainable label for the future. A dialogue between academia, government, the pharmaceutical industry and patient/societal organizations was organized by the Regulatory Science Network Netherlands. This is their view.

Report Issue

If you have problems with the access to a found title, you can use this form to contact us. You can also use this form to write to us if you have noticed any errors in the title display.